Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of zanubrutinib versus ibrutinib in MYD88-mutated Waldenström macroglobulinemia
2016-002980-33Phase 3Completed
- Sponsor
- BeiGene
- Start
- Nov 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Waldenström macroglobulinemia (WM) comparing zanubrutinib with ibrutinib (2 arms). Primary endpoint: Complete response or very good partial response rate. Started Nov 2016; status: completed.
02
Drugs
zanubrutinibibrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2016-002980-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002980-33.